Emerging Drug Developer news from FierceBiotech
News
Emerging Drug Developer: Gemin X Pharmaceuticals
Gemin X Pharmaceuticals Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. Read more...
Gemin X Pharmaceuticals
Pharma development chief takes on role of biotech entrepreneur Over the past 20 years, Glenn Gormley, M.D., Ph.D., rose to a high altitude in the world of big pharma drug development. There were Read more...
Emerging Drug Developer: Immune Design
Immune Design Boom times in the vaccine industry have helped breed a new generation of vaccine Read more...
Emerging Drug Developer: Immune Design
Immune Design starts recruiting for new research Up until a few years ago, vaccine development was in a torpor. Margins were slim, the manufacturing process difficult and the upside often hard to Read more...
Emerging Drug Developer: Juvaris BioTherapeutics
Juvaris ramps up its clinical vaccine programs When Kleiner Perkins Caufield & Byers set up its pandemic and biodefense fund, its lead partner on the initiative--Thomas Monath, M.D.--was Read more...
Emerging Drug Developer: Itero Biopharmaceuticals
Itero adopts a ‘high-tech' development strategy Bryan Lawlis, Ph.D, has found a niche in the biotech industry in which he plans to grow a new biotech company. But don't ask him for the inside Read more...
Emerging Drug Developer: Astex Therapeutics
Two years after FierceBiotech picked Astex Therapeutics in the UK as one of our Fierce 15 companies to watch, the biotech company is still rolling up Read more...
Emerging Drug Developer: Kythera Biopharmaceuticals
Kythera hopes to help shape the future of aesthetic medicine Keith Leonard is an optimist. Mulling over the prospects of Kythera Biopharmaceuticals after its Read more...
Emerging Drug Developer: Auspex Pharmaceuticals
Promise of deuterium lures biotech vet to Auspex When Ajit Gill retired from Nektar Therapeutics after a 14-year stint, he was ready for something new. Nektar had swelled into a developer with a big Read more...
Emerging Drug Developer: Resolvyx Pharmaceuticals
Resolvyx builds on a 100-million-year toxicity study Resolvyx Pharmaceuticals is taking a cue from nature and turning it into new therapeutics. In their case, the cue comes from the tonic qualities Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends